СИНДРОМ ФИБРОМИАЛГИИ: КЛИНИЧЕСКАЯ КАРТИНА, ДИАГНОСТИКА И ЛЕЧЕНИЕ
##article.subject##:
фибромиялгия, симптомлар, терапия, касаллик, даволаш, диагностика, дори, оғриқ, симптомлар мажмуаси##article.abstract##
Мақола энг кенг тарқалган ревматологик касалликлардан бири бўлган фибромиялгия синдромига бағишланган. Фибромиялгия клиник амалиётда энг қийин муаммолардан биридир. Муҳокама масалалари - бу клиник симптомларни шакллантириш, нозологик мустақиллик ва даволашнинг устувор усулларини танлаш масалалари. Бугунги кунга келиб, фибромиялгия даволаш самарадорлиги бўйича рандомизе текширувлар сони сезиларли даражада ошди. Бу касалликни даволашда устувор йўналишларни аниқлашга имкон берди. Диагностика ва даволаш бўйича батафсил маълумот тадқиқотда келтирилган.
Библиографические ссылки
Arnold L.M., Rosen A., Pritchett Y.L. et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder // Pain. 2005; 119 (1–3): P. 5–15.
Bennett M.I, Tai Y.M. Intravenous lignocaine in the management of primary fibromyalgia syndrome // Int J Clin Pharmacol Res. 1995; 15 (3): P. 115–119.
Crofford L.J., Rowbotham M.C., Mease P.J. et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial // Arthritis Rheum. 2005; 52 (4): P.1264–1273.
Crofford L. J., Mease P. J., Simpson S. L. et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-months, double-blind, placebo-controlled trial with pregabalin // Pain. 2008; 136: P.419–431.
Fishbain D.A., Cutler R. B., Rosomoff H. L. et al. Clonazepam open clinical treatment trial for myofascial syndrome associated chronic pain // Pain Med. 2000; 1 (4): P. 332–339.
Jones K. D., Adams D., Winters-Stone K. et al. A comprehensive review of 46 exercise treatment studies in fibromyalgia (1988–2005) // Health Qual Life Outcomes. 2006; 4: P. 67–73.
Hauser W., Bernardy K., Uceyler N. et al. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials // Pain. 2009; 145 (1–2): P.69–81.
Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment // J Rheumatol. 2005; 32, suppl. 75: P. 6–21.
Mease P. J., ClauwD. J., Gendreau R. M. et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial // J Rheumatol. 2009; 36 (2): ;P. 398–409.
Russell I. J., Fletcher E. M., Michalek J. E. et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study // Arthritis Rheum. 1991; 34 (5): P. 552–556.
Straube S., Derry S., Moore R., McQuay H. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports // Rheumatology. 2010; 49: P. 706–715.
Tofferi J. K., Jackson J. L., O’Malley P. G. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis // Arthritis Rheum. 2004; 51 (1): P. 9–13.
Xaio Y., Michalek J. E., Russell I. J. Effects of tizanidine on cerebrospinal fluid substance P in patients with fibromyalgia. In: Saper JR, editor. Alpha-2 adrenergic agonists: evidence and experience examined. Worcester, UK: The Royal Society of Medicine Press, The Trinity Press, 2002: P. 23–28.
